Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery

被引:0
作者
Jennica L. Zaro
机构
[1] University of Southern California,Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy
来源
The AAPS Journal | 2015年 / 17卷
关键词
drug delivery; fatty acids; glyceride; phospholipid; prodrug;
D O I
暂无
中图分类号
学科分类号
摘要
The combination of lipid drug delivery systems with prodrugs offers several advantages including improved pharmacokinetics, increased absorption, and facilitated targeting. Lipidization and use of lipid carriers can increase the pharmacological half-life of the drug, thus improving pharmacokinetics and allowing less frequent dosing. Lipids also offer advantages such as increased absorption through the intestines for oral drug absorption and to the CNS for brain delivery. Furthermore, the use of lipid delivery systems can enhance drug targeting. Endogenous proteins bind lipids in the blood and carry them to the liver to enable targeting of this organ. Drugs with significant side effects in the stomach can be specifically delivered to enterocytes by exploiting lipases for prodrug activation. Finally, lipids can be used to target the lymphatic system, thus bypassing the liver and avoiding first-pass metabolism. Lymphatic targeting is also important for antiviral drugs in the protection of B and T lymphocytes. In this review, both lipid-drug conjugates and lipid-based carriers will be discussed. An overview, including the chemistry and assembly of the systems, as well as examples from the clinic and in development, will be provided.
引用
收藏
页码:83 / 92
页数:9
相关论文
共 388 条
[1]  
Smith DA(1985)Chromone-2-carboxylic acids: roles of acidity and lipophilicity in drug disposition Drug Metab Rev 16 365-388
[2]  
Brown K(2009)Albumin as fatty acid transporter Drug Metab. Pharmacokinet 24 300-307
[3]  
Neale MG(2013)Fatty acids as therapeutic auxiliaries for oral and parenteral formulations Adv Drug Deliv Rev 65 1331-1339
[4]  
van der Vusse GJ(1974)BRL.8988 (talampicillin), a well-absorbed oral form of ampicillin Antimicrob Agents Chemother 5 670-671
[5]  
Hackett MJ(1997)Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume J. Pharmacol. Exp. Ther 281 93-102
[6]  
Zaro JL(1996)Improved passive oral delivery via prodrugs Adv Drug Deliv Rev 19 131-148
[7]  
Shen WC(2011)Intestinal lymphatic transport for drug delivery Adv Drug Deliv Rev 63 923-942
[8]  
Guley PC(1996)Targeting of drug to the hepatocytes by fatty acids. Influence of the carrier (albumin or galactosylated albumin) on the fate of the fatty acids and their analogs Pharm Res 13 27-31
[9]  
Cho MJ(2010)Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions J. Control. Release : Off J. Control. Release Society 142 214-220
[10]  
Clayton JP(2000)Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J Pharm Sci 89 1073-1084